Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.70 |
| ▸ | FAP | Q12884 | 1/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Anhydrous SCHEMBL18894359 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL2040329 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL497725 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL39724 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL18492311 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL20295138 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL19586794 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL3133933 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL400718 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL22206868 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485157-B2 | Method of treating COVID-19 | PFIZER INC. (US) | 2025-12-02 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR BIOTECHNOLOGY INC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. | 2025-10-02 | — | — | US | claimed |
| US-20250191770-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2025-06-12 | — | — | US | claimed |
| EP-4526338-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4526339-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| EP-4329743-A1 | PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES | Birkenmeier, Gerd (DE) | 2024-03-06 | — | — | EP | claimed |
| US-20240060131-A1 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2024-02-22 | — | — | US | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| WO-2022208262-A1 | ETHER-LINKED ANTIVIRAL COMPOUNDS | PFIZER INC. (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022160323-A1 | APPLICATION OF NUCLEOSIDE ANALOGUE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING GASTROINTESTINAL DISEASES | 兰州大学 | 2022-08-04 | — | — | WO | claimed |
| WO-2022135486-A1 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | 中国科学院动物研究所 | 2022-06-30 | — | — | WO | claimed |
| CN-114432314-A | Compound tablet of doriravir and tenofovir and lamivudine | 上海迪赛诺药业股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-114369120-A | Preparation method of key intermediate of prophenoltenofovir | 石家庄龙泽制药股份有限公司 | 2022-04-19 | — | — | CN | claimed |
| EP-3969588-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | VIR Biotechnology, Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| WO-2022047311-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2022-02-24 | — | — | US | claimed |
| EP-3953361-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF COVID-19 | Pfizer Inc. (US) | 2022-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485157-B2 | Method of treating COVID-19 | ACE2, ACE, TMPRSS2 | CYP3A4 517/4885CYP2D6 1047/4885FAP 88/4885 |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | DNTT, HAVCR2, POLRMT | CYP3A4 4467/4885CYP2D6 4014/4885FAP 3561/4885 |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HAVCR2, HLA-B, HDGF | CYP3A4 3704/4885CYP2D6 3721/4885FAP 1447/4885 |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | IFNAR1, IFNG, HAVCR2 | CYP3A4 4333/4885CYP2D6 4334/4885FAP 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.